{"filings":[{"id":695276,"accession_number":"0001193125-26-241840","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2026-05-27T20:00:58+00:00","items":["5.07"],"status":"ready","headline":"Cytokinetics shareholders re-elect three Class I directors and approve all four proposals at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Edward M. Kaye, Wendell Wierenga, and Nancy J. Wysenski re-elected as Class I directors; Wierenga received 85.4M for vs 22.4M withheld.","ESPP amendment approved to increase authorized shares by 1,000,000; 107.3M for, 261k against.","Ernst & Young LLP ratified as auditor for FY 2026; 115.5M for, 269k against.","Advisory vote on executive compensation passed with 104.0M for, 3.0M against.","Quorum of 93.47% of eligible shares represented at meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91010,"accession_number":"0001193125-26-214606","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cytokinetics prices $760M public offering of 11.34M shares at $71/sh","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 9,859,155 shares at $71.00 per share; underwriters' option for 1,478,873 shares exercised in full.","Net proceeds of approximately $760.2 million after underwriting discounts and expenses.","Underwriters include Morgan Stanley, Goldman Sachs, J.P. Morgan, and Jefferies.","Offering made under automatic shelf registration statement filed February 27, 2025.","Prospectus supplement dated May 6, 2026 filed with SEC on May 7, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91009,"accession_number":"0001193125-26-206420","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cytokinetics files corporate presentation; no specific financial or clinical updates disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing states release of current corporate presentation as Exhibit 99.1, incorporated by reference.","No financial results, clinical data, or guidance changes are apparent from the provided exhibit text.","Event is a routine update of investor materials without material new information disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91008,"accession_number":"0001193125-26-206360","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytokinetics reports Q1 2026: MYQORZO net product rev $4.8M, net loss $206M; ACACIA-HCM meets endpoints","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["MYQORZO net product revenue $4.8M for ~9 weeks; total revenue $19.4M (incl $11.9M milestone from Bayer).","Net loss $206.0M ($1.67/sh) vs $161.4M loss in Q1 2025; cash $1.1B (down $144M from Dec 2025).","ACACIA-HCM met dual primary endpoints (KCCQ and peak VO2) in non-obstructive HCM; full results at upcoming medical congress.","Over 275 HCPs prescribed MYQORZO to ~680 patients in Q1; European Commission approved for oHCM.","FY 2026 GAAP combined R&D and SG&A guidance maintained at $830M-$870M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":19355000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100884,"accession_number":"0001193125-26-067012","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytokinetics Q4 net loss $183M; MYQORZO launch underway; cash $1.22B; guides 2026 spend $830-870M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2025 $183M ($1.50/sh) vs $150M ($1.26) Q4 2024; full year loss $785M ($6.54) vs $589.5M ($5.26).","Revenue Q4 $17.8M (up 5% YoY); full year $88.0M (up 376% YoY) from Bayer tech transfer $52.4M and Sanofi milestones $15.0M.","Cash $1.22B at Dec 31 2025; Q4 cash burn ~$134M excluding $100M loan draw from Royalty Pharma.","MYQORZO (aficamten) approved for oHCM in US (Dec 2025), China, EU; US launch underway Jan 2026; ACACIA-HCM topline expected Q2 2026.","FY 2026 GAAP combined R&D+SG&A guidance $830-870M; non-cash stock comp $130-120M."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":88039000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100883,"accession_number":"0001193125-26-053049","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cytokinetics announces European Commission approval of MYQORZO (aficamten) for obstructive HCM","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["European Commission approved MYQORZO (aficamten) for symptomatic obstructive HCM in adults.","Approved dosage strengths: 5 mg, 10 mg, 15 mg, and 20 mg tablets.","MYQORZO is an allosteric, reversible inhibitor of cardiac myosin motor activity.","Indication covers NYHA class II-III obstructive hypertrophic cardiomyopathy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117203,"accession_number":"0001193125-25-326778","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cytokinetics receives FDA approval for MYQORZO (aficamten) to treat symptomatic oHCM","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved MYQORZO (aficamten) on Dec 19, 2025 for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).","MYQORZO is an allosteric, reversible inhibitor of cardiac myosin motor activity, reducing contractility and LVOT obstruction.","Available in 5 mg, 10 mg, 15 mg, and 20 mg tablets.","Approval based on data showing improved functional capacity and symptoms in oHCM patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117202,"accession_number":"0001193125-25-316904","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CHMP recommends EU approval of Cytokinetics' MYQORZO for obstructive HCM","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CHMP adopted positive opinion recommending EU marketing authorization for MYQORZO (aficamten).","Indicated for symptomatic (NYHA class II-III) obstructive hypertrophic cardiomyopathy in adults.","European Commission final decision expected in Q1 2026.","MYQORZO is a cardiac myosin inhibitor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117201,"accession_number":"0001193125-25-282889","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cytokinetics appoints Jeffrey Hessekiel as EVP, Chief Legal and Administrative Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective Nov 14, 2025; Hessekiel previously EVP & General Counsel at Exelixis (2014-2025).","Annual base salary of $660,000 and target bonus of 50% of base salary.","Signing bonus of $400,000 payable 50% on first payroll cycle and 50% after one year.","Initial RSU award of $5,800,000 grant-date value vests 40/40/20 over three years.","Eligible for company benefit plans, 2004 Equity Incentive Plan, and Executive Severance Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117200,"accession_number":"0001193125-25-266842","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytokinetics Q3 net loss $306M; aficamten PDUFA on track; raises $750M convertible notes","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss $306.2M ($2.55/share) vs $160.5M loss in prior year; includes $121.2M debt conversion expense.","Cash, cash equivalents & investments $1.25B at Sep 30; raised $750M 1.75% convertible notes due 2031, used $402.5M to retire $399.5M of 2027 notes.","PDUFA date for aficamten NDA remains Dec 26, 2025; commercial launch preparations on track.","Updated FY2025 GAAP operating expense guidance to $680M-$700M (prior $670M-$710M).","Total Q3 revenue $1.9M (vs $0.5M); R&D $99.2M, G&A $69.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":70284000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133645,"accession_number":"0001193125-25-209437","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2025-09-22T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Cytokinetics issues $750M 1.75% convertible notes; refinances $399.5M of 2027 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $750M aggregate principal of 1.75% convertible senior notes due 2031; net proceeds ~$729.4M.","Used ~$402.5M cash and 2,168,806 common shares to exchange $399.5M of existing 3.50% notes due 2027.","Initial conversion price ~$68.42 per share, ~37.5% premium over $49.76 last sale price.","Remaining proceeds to fund aficamten commercial launch, development, pipeline, and general corporate purposes.","Notes not redeemable before Oct 6, 2028; convertible under certain stock price and event conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133644,"accession_number":"0001193125-25-204991","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cytokinetics provides FDA/EMA update on aficamten; plans to draw $100M Royalty Pharma loan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA Late Cycle Meeting held; discussed REMS and label for aficamten in oHCM; PDUFA date remains Dec 26, 2025.","GCP inspections completed with no observations; no GMP inspections scheduled for aficamten.","Submitted responses to CHMP Day 120 questions from EMA for aficamten potential EU approval.","Intends to draw full $100M Tranche 5 term loans from Royalty Pharma on or about October 1, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133639,"accession_number":"0000950170-25-113599","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K/A","filed_at":"2025-09-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cytokinetics presents positive aficamten data at ESC 2025; PDUFA Dec 26, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MAPLE-HCM: aficamten improved cardiac structure/function vs metoprolol (p<0.001 for diastolic function, SAM reduction); published in JACC.","New analysis shows aficamten AF incidence 1.5%/year, consistent with HCM prediction model (3.6%/year) and healthy model (1.4%/year); published in Heart Rhythm.","FOREST-HCM: 93% of patients had ≥1 NYHA class improvement at 96 weeks; sustained hemodynamic benefits with low LVEF <50% (0.3% discontinuation).","Integrated safety (463 patients, ~700 patient-years): aficamten well-tolerated, AE profile similar to placebo; new-onset AF 1.9% vs placebo 2%.","FDA NDA under review; PDUFA target action date December 26, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133643,"accession_number":"0000950170-25-112570","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cytokinetics presents new aficamten data at ESC 2025; shows improvement vs metoprolol","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MAPLE-HCM: aficamten superior to metoprolol on diastolic function, SAM, and LVOT obstruction (p<0.001); reduced max wall thickness (-1.01mm, p=0.015).","Atrial fibrillation annual incidence with aficamten was 1.5%, consistent with predicted HCM-AF and CHARGE-AF rates; minimal clinical impact.","Integrated safety of 463 patients (~700 patient-years) shows similar AE profile to placebo; low LVEF<50% incidence, no permanent discontinuations.","Longer-term FOREST-HCM: 69% and 93% of patients improved NYHA class at Week 12 and 96; KCCQ-CSS +15 and +16.","FDA NDA under review with PDUFA target action date of December 26, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133642,"accession_number":"0000950170-25-112564","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aficamten superior to metoprolol in MAPLE-HCM Phase 3 trial; primary endpoint met (p<0.0001)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Least-squares mean pVO2 difference: +2.3 mL/kg/min (95% CI 1.5 to 3.1; p<0.0001) favoring aficamten.","51% of aficamten patients improved ≥1 NYHA class vs 26% on metoprolol (p<0.001).","Aficamten reduced NT-proBNP by 81% vs metoprolol (p<0.0001); 1 patient had LVEF<50%.","FDA PDUFA target action date for aficamten NDA is December 26, 2025.","Results published simultaneously in The New England Journal of Medicine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133641,"accession_number":"0000950170-25-110368","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cytokinetics appoints James M. Daly to Board of Directors as Class III member","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James M. Daly appointed to Board effective August 19, 2025, as Class III director, term expiring at 2028 annual meeting.","Daly also appointed to Compliance Committee; determined independent under SEC and Nasdaq rules.","Annual director compensation: $50,000 retainer, $7,500 Compliance retainer, plus $440,000 equity grant.","Initial option grant of 27,450 shares ($700,000 fair value) vesting over three years.","No arrangements or transactions requiring disclosure under Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133640,"accession_number":"0000950170-25-104962","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytokinetics Q2 net loss narrows to $134.4M; aficamten PDUFA set Dec 26, 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $134.4M ($1.12/sh) vs $143.3M ($1.31/sh) in Q2 2024; revenue $66.8M from Bayer deal.","Cash, cash equivalents and investments: $1.0B at June 30, down $52.6M QoQ after $75M loan draw.","FDA late-cycle meeting for aficamten (obstructive HCM) scheduled Sept 2025; PDUFA Dec 26, 2025.","MAPLE-HCM primary results to be presented in Hot Line Session at ESC 2025.","FY 2025 GAAP operating expense guidance maintained at $670M-$710M."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":68348000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150350,"accession_number":"0000950170-25-072965","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cytokinetics shareholders double authorized shares to 326M; approve equity plan amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock increased from 163M to 326M shares, approved with 107.3M votes for, 3.0M against.","Equity incentive plan amended to add 5.0M authorized shares and cap non-executive director grants ($1M annual, $1.25M initial).","Elected Class III directors John T. Henderson, B. Lynne Parshall, and Muna Bhanji with majority support.","Ratified Ernst & Young as independent auditor for FY2025 with 110.3M votes for.","Advisory vote on executive compensation passed with 96.8M votes for, 4.6M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150349,"accession_number":"0000950170-25-064432","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytokinetics Q1 net loss $161.4M; aficamten PDUFA extended to Dec 26, 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $161.4M ($1.36/share) vs $135.6M ($1.33/share) in Q1 2024; revenue $1.6M.","FDA extended aficamten PDUFA date for obstructive HCM to Dec 26, 2025 due to REMS submission; no additional clinical data requested.","MAPLE-HCM topline results expected May 2025; ACACIA-HCM enrollment completed, topline 1H 2026.","Cash, cash equivalents, and investments ~$1.1B at Mar 31, down $132.2M from Dec 31, 2024.","Full-year 2025 GAAP operating expense guidance maintained at $670-710M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":1579000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150348,"accession_number":"0000950170-25-061847","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cytokinetics announces FDA extends aficamten PDUFA date to Dec 26, 2025 on REMS review","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA extended PDUFA date for aficamten NDA in oHCM to December 26, 2025, a three-month extension.","Extension due to FDA requesting a Risk Evaluation and Mitigation Strategy (REMS) as a Major Amendment.","No additional clinical data or studies requested; NDA originally filed without REMS.","Cytokinetics submitted the REMS after FDA request; review continues."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169337,"accession_number":"0000950170-25-035914","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Cytokinetics: FDA won't hold adcom for aficamten NDA; Late Cycle meeting set for June 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Cytokinetics completed midcycle review with FDA for aficamten NDA treating obstructive hypertrophic cardiomyopathy.","FDA informed Cytokinetics it does not plan to convene an advisory committee meeting for the aficamten NDA.","Late Cycle meeting with FDA expected in June 2025; company maintains expectation for differentiated label and risk mitigation if approved.","Cytokinetics does not plan to share detailed updates on FDA communications beyond this update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169336,"accession_number":"0000950170-25-029017","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytokinetics Q4 net loss $150M, cash $1.2B; aficamten PDUFA date Sept 26, 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2024 was $150.0M ($1.26/sh) vs $136.9M ($1.38/sh) in Q4 2023; FY net loss $589.5M.","Cash, cash equivalents and investments ~$1.2B at Dec 31, 2024, down ~$60M from Sept 30, 2024.","FDA accepted aficamten NDA with target PDUFA date of September 26, 2025; MAA validated in Europe.","Topline results from Phase 3 MAPLE-HCM trial expected in Q2 2025.","2025 GAAP operating expense guidance: $670M-$710M; non-cash stock comp $110M-$120M."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":18474000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169335,"accession_number":"0000950170-25-017458","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cytokinetics appoints Robert E. Landry to Board of Directors, effective Feb 10, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert E. Landry appointed as Class II director, term expiring at 2027 annual meeting.","Also appointed to Audit Committee; Board determined independent under SEC and Nasdaq rules.","Compensation includes $50k annual retainer, $12.5k Audit Committee retainer, and annual equity grant of $440k.","Received initial option grant of 25,538 shares with $700k grant date fair value, vesting over three years.","Standard indemnification agreement entered into; no other arrangements or transactions requiring disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186364,"accession_number":"0000950170-24-136695","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cytokinetics CAO Robert Wong to depart Dec 31; CFO Lee to serve as principal accounting officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Wong, Chief Accounting Officer, will leave Cytokinetics effective December 31, 2024.","No disagreement between Wong and the Company regarding financial condition or reporting.","CFO Sung Lee, age 54, will additionally assume role of principal accounting officer upon Wong's departure.","Lee joined as CFO in May 2024; prior roles include CFO at Vir Biotechnology and MorphoSys AG."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186363,"accession_number":"0000950170-24-128266","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2024-11-19T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Cytokinetics licenses aficamten Japan rights to Bayer for €50M upfront, up to €580M milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront payment of €50 million from Bayer; additional clinical/commercial launch milestones up to €90 million.","Commercial milestone payments up to €490 million based on net sales thresholds.","Tiered royalties on Japan net sales ranging from high-teens to low-thirty percent.","Bayer responsible for development and commercialization at its own cost; Cytokinetics retains rights to ACACIA-HCM and CEDAR-HCM trials in Japan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186362,"accession_number":"0000950170-24-123277","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Santo J. Costa resigns from Cytokinetics board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Santo J. Costa resigned from the Board of Directors on November 1, 2024.","Resignation for personal reasons; no disagreement with company policies or operations.","Board size reduced from nine to eight directors effective immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202986,"accession_number":"0000950170-24-097556","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cytokinetics hires Brett Pletcher as EVP, Chief Legal Officer effective Aug 19, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Annual base salary $560,000; target bonus 45% of base under Bonus Plan.","Signing bonus $100,000, repayable if resignation or termination for cause within 12 months.","Initial equity: ~$1.89M RSUs, ~$1.89M option grant, and performance stock units with $833,520 target value.","Vesting: RSUs 40/40/20 over 3 years; options 25% cliff then monthly, PSUs vest over 2 years after certification.","Pletcher was Of Counsel at Gunderson Dettmer; prior EVP, General Counsel at Gilead Sciences."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202985,"accession_number":"0000950170-24-093855","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cytokinetics Q2 net loss widens to $1.31/share; cash rises to $1.4B on $563M offering and $250M Royalty Pharma deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $143.3M ($1.31/share) vs $128.6M ($1.34/share) in Q2 2023; revenue down to $0.2M from $0.9M.","Cash & investments $1.4B as of June 30, 2024, up from $634.3M at March 31, aided by $563.2M public offering and $250M upfront from Royalty Pharma.","Rolling NDA for aficamten underway; Type B meeting with FDA held on risk mitigation; submission on track for Q3 2024.","FDA cleared FOREST-HCM protocol amendment reducing echo monitoring frequency for obstructive HCM patients.","Updated 2024 GAAP OpEx guidance raised to $555M-$575M (prev $535M-$555M); net cash use unchanged at $400M-$420M."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":1084000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219239,"accession_number":"0001193125-24-157531","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cytokinetics raises ~$75M from underwriters' full exercise of overallotment option","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwriters purchased 1,470,588 additional shares at $51.00 per share on June 7, 2024.","Gross proceeds of approximately $75 million before underwriting discounts and commissions.","Option exercised under May 22, 2024 underwriting agreement for initial offering of 9,803,922 shares.","Total shares sold in offering now 11,274,510; combined gross proceeds ~$575 million.","Net proceeds will be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219238,"accession_number":"0000950170-24-069098","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cytokinetics discloses third-party acquisition approach, no deal reached","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cytokinetics was approached by a third party for a full acquisition after SEQUOIA-HCM top-line results in Dec 2023.","Board supported moving forward on substantially agreed terms, but the third party did not proceed.","CEO states Board and management are committed to shareholder value and would support any value-maximizing transaction.","Company will not comment further on this matter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219237,"accession_number":"0001193125-24-148077","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cytokinetics closes $500M public equity offering; concurrent $50M private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed public offering of 9,803,922 shares at $51.00; gross proceeds ~$500M.","Underwriters have 30-day option for additional 1,470,588 shares; potential $575M total.","Concurrent private placement to Royalty Pharma for 980,392 shares at $51.00 per share.","Offering led by J.P. Morgan, Goldman Sachs, and Morgan Stanley; closed May 28, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219236,"accession_number":"0001193125-24-144965","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cytokinetics releases corporate presentation; no details available for summary","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate presentation released on May 22, 2024, as Exhibit 99.1.","No financial or operational data from the presentation was included in the filing.","Investors directed to the presentation for updates on pipeline and strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219235,"accession_number":"0001193125-24-144956","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["1.01","2.01","2.03"],"status":"ready","headline":"Cytokinetics secures $200M immediate funding from Royalty Pharma; restructures aficamten royalty","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received $50M upfront from Tranche 6 term loan and $100M from 2024 DFA; plus $50M from CK-586 RPA; total $200M immediate cash.","Aficamten royalty restructured: RPI gets 4.5% up to $5B net sales (was $1B), then 1% above $5B (was 3.5%).","Optional $175M Tranche 7 term loan if FDA approves aficamten for HCM by Dec 31, 2025; repayment at 190% of principal.","CK-586 RPA provides up to $200M total; RPI funds 50% of R&D costs after Phase 3 start; receives 1-4.5% royalty plus milestone payments.","Stock Purchase Agreement allows Cytokinetics to require RPI to buy $50M shares in next equity financing (min $250M gross) by Aug 20, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219234,"accession_number":"0000950170-24-061275","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Cytokinetics director Smith resigns; stockholders approve 300K-share ESPP increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sandford D. Smith resigned from the board effective before the 2024 annual meeting, not due to any disagreement.","Stockholders approved amendment to ESPP increasing authorized shares by 300,000 to total 1,159,879 shares.","Robert I. Blum and Robert A. Harrington elected as Class II directors for three-year terms.","Ernst & Young LLP ratified as independent auditor for 2024; say-on-pay proposal passed advisory vote.","Approximately 91.97% of eligible shares (96,181,650 votes) represented at the meeting, forming a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219233,"accession_number":"0000950170-24-058654","cik":1061983,"company_name":"CYTOKINETICS INC","ticker":"CYTK","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aficamten Phase 3 SEQUOIA-HCM meets primary endpoint: pVO2 improved 1.8 vs 0.0 mL/kg/min (p=0.000002)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 10 prespecified secondary endpoints met, including KCCQ-CSS (+7 points, p<0.0001) and NYHA class improvement (34%, p<0.0001).","Treatment reduced days eligible for septal reduction therapy by 78 days vs placebo (p<0.0001).","No treatment interruptions due to low LVEF; serious adverse events 5.6% aficamten vs 9.3% placebo.","Results presented at ESC Heart Failure 2024 and published in New England Journal of Medicine.","Composite responder endpoint achieved by 42% aficamten vs 14% placebo (p<0.0001)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9599972411.138418,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}